Citryll Raises EUR 85 Million for NET-Targeting Therapy
09 Dec 2024 //
GLOBENEWSWIRE
Citryll Gets Grant For NET Research In Rheumatoid Arthritis
03 Oct 2024 //
GLOBENEWSWIRE
CITRYLL Completes Dosing In Phase 1 Trial Of CIT-013
31 Jul 2024 //
GLOBENEWSWIRE
Citryll Announces the Appointment of Maarten Kraan as Chief Medical Officer
13 Feb 2024 //
BUSINESSWIRE
Citryll Announces Appointment of Paul Peter Tak as Chair of Board of Directors
30 Mar 2023 //
BUSINESSWIRE
Citryll starts dosing of healthy volunteers in Phase 1 for CIT-013.
17 Aug 2021 //
BUSINESSWIRE